Genome-based approaches to vaccine development.
The hundreds of bacterial genome sequences available together with advances in bioinformatics and the development of new experimental proteomic tools are revolutionizing the vaccinology field. The merge of stringent in silico criteria and different experimental approaches is allowing a more targeted strategy to obtain a restricted and prioritized list of potential antigens for testing in immunogenicity assays, reducing the time and the cost of novel protein vaccine formulations.
Mora
Marirosa
M
Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy. john.telford@novartis.com
Telford
John L
JL
D000818:Animals; D000942:Antigens, Bacterial / Q000235:genetics* / Q000276:immunology; D001428:Bacterial Vaccines / Q000235:genetics* / Q000276:immunology; D019295:Computational Biology; D015195:Drug Design; D016680:Genome, Bacterial / Q000235:genetics*; D023281:Genomics / Q000379:methods*; D006801:Humans
D000942:Antigens, Bacterial; D001428:Bacterial Vaccines